Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Solution structure and interactions of a triple negative breast cancer target
EF 2016-17
Résumé
Triple Negative Breast Cancer (TNBC) is a particularly aggressive breast cancer subtype which has no effective cure. Calmodulin Dependent Protein Kinase 1 Delta (CaMK1D), which is overexpressed in 80% of TNBC tumours, has been identified as a putative driver of TNBC and a viable therapeutic target. It has previously been shown that these tumours are susceptible (i.e. decreased proliferation/invasion) to the inhibition of CaMK1D inhibition via siRNA and small molecule inhibitors. Kinases are important for cancer intervention as they play a key role in cell cycle progression signaling pathways, however, the active site in many of these proteins is highly conserved and off-target effects are a threat. The focus of this project will be to characterize binding interactions of drug-like molecules known to inhibit CaMK1D, to identify a new or novel binding pocket and effectively limit toxicity. Firstly, protein backbone and sidechain assignments must be completed via Nuclear Magnetic Resonance (NMR) to give us a clear picture of the CaMK1D structure. Once completed, these assignments will be used to map the binding of drug-like molecules and activators such as Calmodulin via Chemical Shift Perturbations (CSPs). Identification of specific amino acid residue contacts for each molecule will give an accurate picture of fragment binding and aid in the development of more potent and selective inhibitors. This project, through specific targeting of a novel kinase target, has direct application for breast cancer patients with poor prognosis and limited treatment options, and could yield a tumour-specific, first-line therapy with minimal toxicity.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367259
Name
McLennan Steffane D
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Solution structure and interactions of a triple negative breast cancer target
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allostery; Camk1d; Fragment Based Drug Discovery; Phosphorylation; Triple Negative Breast Cancer
Abstract
Triple Negative Breast Cancer (TNBC) is a particularly aggressive breast cancer subtype which has no effective cure. Calmodulin Dependent Protein Kinase 1 Delta (CaMK1D), which is overexpressed in 80% of TNBC tumours, has been identified as a putative driver of TNBC and a viable therapeutic target. It has previously been shown that these tumours are susceptible (i.e. decreased proliferation/invasion) to the inhibition of CaMK1D inhibition via siRNA and small molecule inhibitors. Kinases are important for cancer intervention as they play a key role in cell cycle progression signaling pathways, however, the active site in many of these proteins is highly conserved and off-target effects are a threat. The focus of this project will be to characterize binding interactions of drug-like molecules known to inhibit CaMK1D, to identify a new or novel binding pocket and effectively limit toxicity. Firstly, protein backbone and sidechain assignments must be completed via Nuclear Magnetic Resonance (NMR) to give us a clear picture of the CaMK1D structure. Once completed, these assignments will be used to map the binding of drug-like molecules and activators such as Calmodulin via Chemical Shift Perturbations (CSPs). Identification of specific amino acid residue contacts for each molecule will give an accurate picture of fragment binding and aid in the development of more potent and selective inhibitors. This project, through specific targeting of a novel kinase target, has direct application for breast cancer patients with poor prognosis and limited treatment options, and could yield a tumour-specific, first-line therapy with minimal toxicity.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
McLennan, Steffane D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~